Statin use and the risk of kidney cancer: a population-based case–control study

Bibliography

• Wong WW, Dimitroulakos J, Minden MD, HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apotosis. Leukemia 2002;16:508-19
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 2005;366:1267-78
   PubMed Web of Science ®Google Scholar
• Hebert PR, Gaziano JM, Chan KS, Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997;278:313-21
   PubMed Web of Science ®Google Scholar
• Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA 1996;275:55-60
   PubMed Web of Science ®Google Scholar
• Keyomarsi K, Sandoval L, Band V, Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res 1991;51:3602-9
   PubMed Web of Science ®Google Scholar
• Dimitroulakos J, Marhin WH, Tokunaga J, Microarray and biochemical analysis of lovastatin-induced apotosis of squamous cell carcinoma. Neoplasia 2002;4:337-46
   PubMed Web of Science ®Google Scholar
• Park HJ, Hong D, Iruela-Arispe L, 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ Res 2002;91:143-50
   PubMed Web of Science ®Google Scholar
• Weis M, Heeschen C, Glassford AJ, Statins have biphasic effects on angiogenesis. Circulation 2002;105:739-45
   PubMed Web of Science ®Google Scholar
• Alonso DF, Farina HG, Skilton G, Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Res Treat 1998;50:83-93
   PubMed Web of Science ®Google Scholar
• Kusama T, Mukai M, Iwasaki T, 3-hydroxy-3- methylglutaryl-coenzyme A reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology 2002;122:308-17
   PubMed Web of Science ®Google Scholar
• Kaye JA, Jick H. Statin use and cancer risk in the general practice research database. Br J Cancer 2004;90:635-7
   PubMed Web of Science ®Google Scholar
• Dale KM, Coleman CI, Henyan NN, Statins and cancer risk: a meta-analysis. JAMA 2006;295:74-80
   PubMed Web of Science ®Google Scholar
• Bonovas S, Filioussi K, Tsavaris N, Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials. J Clin Oncol 2006;24:4808-17
   PubMed Web of Science ®Google Scholar
• Browning DR, Martin RM. Statins and risk of cancer: a systematic review and metaanalysis. Int J cancer 2006;120:833-43
   Web of Science ®Google Scholar
• Coogan PF, Rosenberg L, Strom BL. Statin use and the risk of 10 cancers. Epidemiology 2007;18:213-19
   PubMed Web of Science ®Google Scholar
• Haukka J, Sankila R, Klaukka T, Incidence of cancer and statin usage-record linkage study. Int J Cancer 2010;126:279-84
   PubMed Web of Science ®Google Scholar
• Kuoppala J, Lamminpaa A, Pukkala E. Statins and cancer: a systematic review and meta-analysis. Eur J Cancer 2008;44:2122-32
   PubMed Web of Science ®Google Scholar
• Setoguchi S, Glynn RJ, Avorn J, Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation 2007;115:27-33
   PubMed Web of Science ®Google Scholar
• Blais L, Desgagne A, LeLorier J. 3-hydroxy-3-methylglutaryl- coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 2000;160:2363-8
   PubMed Web of Science ®Google Scholar
• Boudreau DM, Gardner JS, Malone KE, The association between 3-hydroxy-3-methylglutaryl-coenzyme A inhibitor use and breast carcinoma risk among postmenopausal women. Cancer 2004;100:2308-16
   PubMed Web of Science ®Google Scholar
• Cauley JA, Zmuda JM, Lui LY, Lipid-lowering drug use and breast cancer in older women: a prospective study. J Womens Health 2003;12:749-56
   PubMed Web of Science ®Google Scholar
• Graaf MR, Beiderbeck AB, Egberts AC, The risk of cancer in users of statins. J Clin Oncol 2004;22:2388-94
   PubMed Web of Science ®Google Scholar
• Poynter JN, Gruber SB, Higgins PD, Statins and the risk of colorectal cancer. N Engl J Med 2005;352:2184-92
   PubMed Web of Science ®Google Scholar
• Shannon J, Tewoderos S, Garzotto M, Statins and prostate cancer risk: a case-control study. Am J Epidemiol 2005;162:318-25
   PubMed Web of Science ®Google Scholar
• Khurana V, Bejjanki HR, Caldito G, Statins reduce the risk of lung cancer: a large case-control study of US veterans. Chest 2007;131:1282-8
   PubMed Web of Science ®Google Scholar
• Khurana V, Sheth A, Caldito G, Statins reduce the risk of pancreatic cancer in humans: a case-control study of half a million veterans. Pancreas 2007;34:260-5
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Johnson ML, Hachem C, Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology 2009;136:1601-8
   PubMed Web of Science ®Google Scholar
• Friis S, Poulsen AH, Johnsen SP, Cancer risk among statin users: a population-based cohort study. Int J Cancer 2005;114:643-7
   PubMed Web of Science ®Google Scholar
• Goldstein MR, Mascitelli L, Pezzetta F. Do statin prevent or promote cancer? Curr Oncol 2008;15:76-7
   PubMed Web of Science ®Google Scholar
• Shepherd J, Blauw GJ, Murphy MB, Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002;360:1623-30
   PubMed Web of Science ®Google Scholar
• Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 1988;62:28J-34J
   PubMed Web of Science ®Google Scholar
• Khurana V, Caldito G, Ankem M. Statins might reduce risk of renal cell carcinoma in humans: case-control study of 500,000 veterans. Urology 2008;71:118-22
   PubMed Web of Science ®Google Scholar
• Chiang CW, Chen CY, Chiu HF, Trends in the use of antihypertensive drugs by outpatients with diabetes in Taiwan, 1997-2003. Pharmacoepidemiol Drug Saf 2007;16:412-21
   PubMed Web of Science ®Google Scholar
• Kuo HW, Tsai SS, Tiao MM, Epidemiologic features of CKD in Taiwan. Am J Kidney Dis 2007;49:46-55
   PubMed Web of Science ®Google Scholar
• Tiao MM, Tsai SS, Kuo HW, Epidemiological features of biliary atresia in Taiwan, a national study 1996 – 2003. J Gastroenterol Hepatol 2008;23:62-6
   PubMed Web of Science ®Google Scholar
• Coogan PF, Rosenberg L, Palmer JR, Statin use and the risk of breast and prostate cancer. Epidemiology 2002;13:262-7
   PubMed Web of Science ®Google Scholar
• Jadhav SB, Jain GK. Statins and osteoporosis: new role for old drugs. J Pharm Pharmacol 2006;58:3-18
   PubMed Web of Science ®Google Scholar
• Meier CR, Scheinger RG, Kraenzlin ME, HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000;283:3205-10
   PubMed Web of Science ®Google Scholar
• Rejnmark L, Plsen ML, Johnsen SP, Hip fracture risk in statin users- a population-based Danish case-control study. Osteoporos Int 2004;15:452-8
   PubMed Web of Science ®Google Scholar
• Wang PS, Solomon DH, Mogun H, HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000;283:3211-16
   PubMed Web of Science ®Google Scholar
• WHO Collaborating Center for Drugs Statistics Methodology. ATC Index with DDDs 2003. WHO; Oslo: 2003
   Google Scholar
• Lindblad P, Chow WH, Chan J, The role of diabetes mellitus in the etiology of renal cell cancer. Diabetologia 1999;42:107-12
   PubMed Web of Science ®Google Scholar
• Chow WH, Gridley G, Fraumeni JF, Obesity, hypertension, and the risk of kidney cancer in men. N Engl Med 2000;343:1305-11
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Fuchs CS, Colditz GA, A prospective study of body mass index, hypertension, and smoking and the risk of renal cell carcinoma (United States). Cancer Causes Control 2005;16:1099-106
   PubMed Web of Science ®Google Scholar
• Goldstein MR. Mascitelli, Pezzetta F. The doubleedged sword of statin immunomodulation. Int J Cardiol 2009;135:128-30
   PubMed Web of Science ®Google Scholar
• Mausner-Fainberg K, Luboshits G, Mor A, The effect of HMG-CoA reductase inhibitors on naturally occurring CD+4CD+25 T cells. Atherosclerosis 2008;197:829-39
   PubMed Web of Science ®Google Scholar
• Raemer PC, Kohl K, Watzl C. Statins inhibit NK-cell cytotoxicity by interfering with LFA-1-mediated conjugate formation. Eur J Immunol 2009;39:1456-65
   PubMed Web of Science ®Google Scholar
• Kobashigawa JA, Katznelson S, Laks H, Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995;333:621-7
   PubMed Web of Science ®Google Scholar
• Blanco-Colio LM, Villa A, Ortego M, 3-hydroxy-3- methylglutaryl-coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apotosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis 2002;161:17-26
   PubMed Web of Science ®Google Scholar
• Danesh FR, Sadeghi MM, Amro N, 3-hydroxy-3- methylglutaryl-coenzyme A reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/p21 signaling pathway: implications for diabetic nephropathy. Proc Natl Acad Sci 2002;99:8301-5
   PubMed Web of Science ®Google Scholar
• Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3- methylglutaryl-coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001;21:1712-19
   PubMed Web of Science ®Google Scholar
• Shibata MA, Avanaugh C, Shibata E, Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models. Carcinogenesis 2003;24:453-9
   PubMed Web of Science ®Google Scholar
• Rao S, Porter DC, Chen X, Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci 1999;96:7797-802
   PubMed Web of Science ®Google Scholar
• Kuo HW, Tsai SS, Tiao MM, Analgesic use and the risk for progression of chronic kidney disease. Pharmacoepidemiol Drug Saf 2010;19:745-51
   PubMed Web of Science ®Google Scholar
• Eichholzer M, Stahelin HB, Gutzwiller F, Association of low plasma cholesterol with mortality for cancer at various sites in men: 17-y follow-up of the prospective Basel study. Am J Clin Nutr 2007;71:569-74
   Google Scholar
• Iribarren C, Reed DM, Chen R, Low serum cholesterol and mortality, which is the cause and which is the effect? Circulation 1995;92:2396-403
   PubMed Web of Science ®Google Scholar
• Winawer SJ, Flehinger BJ, Buchalter J, Declining serum cholesterol levels prior to diagnosis of colon cancer. A time-trend, case-control study. J Am Med Assoc 1990;263:2083-5
   PubMed Web of Science ®Google Scholar